JP Morgan Chase
DMAC icon

JP Morgan Chase’s DiaMedica Therapeutics DMAC Stock Holding History

JP Morgan Chase’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$95.1K Buy
14,316
+757
+6% +$6K ﹤0.01% 5863
2025
Q4 		$108K Buy
13,559
+774
+6% +$5.79K ﹤0.01% 5840
2025
Q3 		$87.8K Buy
12,785
+302
+2% +$1.64K ﹤0.01% 5971
2025
Q2 		$48.7K Buy
+12,483
New +$48.7K ﹤0.01% 5937
2024
Q4 		– Sell
-27
Closed -$113 – 7448
2024
Q3 		$113 Buy
+27
New +$100 ﹤0.01% 6983
2024
Q1 		– Sell
-564
Closed -$1.6K – 7495
2023
Q4 		$1.6K Buy
564
+539
+2,156% +$1.33K ﹤0.01% 6752
2023
Q3 		$65 Buy
25
+4
+19% +$13 ﹤0.01% 6959
2023
Q2 		$91 Buy
+21
New +$51 ﹤0.01% 6705
2021
Q3 		– Sell
-8,299
Closed -$37K – 6537
2021
Q2 		$37K Buy
+8,299
New +$68K ﹤0.01% 5813
2020
Q4 		– Sell
-8
Closed – – 5689
2020
Q3 		$0 Hold
8
– – ﹤0.01% 5528
2020
Q2 		$0 Buy
+8
New +$36 ﹤0.01% 5436

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase's DMAC Position: Q1 2026 in Review

JP Morgan Chase increased its DiaMedica Therapeutics (DMAC) stake by 5.6% in Q1 2026, buying an estimated $6K and bringing the position to 14,316 shares worth $95.1K. The position accounts for ﹤0.01% of the portfolio, ranked #5863.

JP Morgan Chase first reported a position in DMAC in Q2 2020 and has held it in 11 quarters since. The position peaked at $108K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • JP Morgan Chase held 14,316 shares of DiaMedica Therapeutics worth $95.1K as of Q1 2026.
  • JP Morgan Chase bought 757 DiaMedica Therapeutics shares in Q1 2026, an estimated $6K.
  • DiaMedica Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5863 holding.
  • JP Morgan Chase first reported a position in DiaMedica Therapeutics in Q2 2020 and has held it in 11 quarters since.
  • JP Morgan Chase's DiaMedica Therapeutics position peaked at $108K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.